08 Oct 2020 - CSL (ASX:CSL) subsidiary, Seqirus, has signed a final agreement with the Commonwealth of Australia for the supply of 51 million doses of the University of Queensland-CSL Covid-19 vaccine candidate, should clinical trials be successful.